Premium
Tumour‐associated glycan modifications of antigen enhance MGL2 dependent uptake and MHC class I restricted CD8 T cell responses
Author(s) -
Singh Satwinder Kaur,
StrengOuwehand Ingeborg,
Litjens Manja,
Kalay Hakan,
Saeland Eirikur,
van Kooyk Yvette
Publication year - 2011
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.25458
Subject(s) - antigen , glycan , antigen presentation , cross presentation , cd8 , immunology , mhc class ii , major histocompatibility complex , cytotoxic t cell , biology , t cell , mhc class i , antigen presenting cell , dendritic cell , antigen processing , microbiology and biotechnology , immune system , biochemistry , glycoprotein , in vitro
We recently showed that MGL2 specifically binds tumour‐associated glycan N ‐acetylgalactosamine (GalNAc). We here demonstrate that modification of an antigen with tumour‐associated glycan GalNAc, targets antigen specifically to the MGL2 on bone marrow derived (BM)‐DCs and splenic DCs. Glycan‐modification of antigen with GalNAc that mimics tumour‐associated glycosylation, promoted antigen internalisation in DCs and presentation to CD4 T cells, as well as differentiation of IFN‐γ producing CD4 T cells. Furthermore, GalNAc modified antigen enhanced cross‐presentation of both BM‐DCs and primary splenic DCs resulting in enhanced antigen specific CD8 T cell responses. Using MyD88‐TRIFF −/− BM‐DCs we demonstrate that the enhanced cross‐presentation of the GalNAc modified antigen is TLR independent. Our data strongly suggest that tumour‐associated GalNAc modification of antigen targets MGL on DCs and greatly enhances both MHC class II and class I presentation in a TLR independent manner.